LLP-3 是一种有效的Survivin抑制剂,可扰乱癌细胞中的 Survivin-Ran 蛋白复合物作用。LLP-3 可用于多形性胶质母细胞瘤(GBM) 的研究。
生物活性 | LLP-3 is a potentSurvivininhibitor that disrupts the Survivin-Ran interaction incancercells. LLP-3 can be used in the research of Glioblastoma multiforme (GBM)[1]. |
IC50& Target | |
体外研究 (In Vitro) | LLP-3 (20 μM, 24 h) impaires the binding of Survivin to Smac/DIABLO (proapoptotic protein), without affecting the interaction of Survivin with other chromosomal passenger complex (CPC) proteins[1]. LLP-3 (20 μM, 24 h) decreases the Survivin-Ran interaction in U87 cells[1]. LLP-3 (20 μM, 24 h) arrests cell in G0-G1 phase and subsequent tumor cell death[1]. LLP-3 (20 μM, 24 h) triggers caspase-dependent apoptosis in HT1080 cells[1]. LLP-3 (0-100 μM, 72 h) inhibits tumor cells survival by p53-mediated inhibition[1].
Cell Viability Assay[1] Cell Line: | U87E6, U87MG cell | Concentration: | 0-100 μM | Incubation Time: | 72 h | Result: | Inhibited tumor cells survival with IC50values of 13.6 μM (U87E6) and 38.1 μM (U87MG). |
Cell Cycle Analysis[1] Cell Line: | U87 cells | Concentration: | 20 μM | Incubation Time: | 24 h | Result: | Reduced the proportions of cells in the S and G2-M phases (from 9% to 5%, and from 25% to 17%, respectively). Increased G0-G1 cell population (from 60% to 74%). |
Immunofluorescence[1] Cell Line: | U87, HT1080 cells | Concentration: | 40 μM | Incubation Time: | 24 h | Result: | Weakened the colocalization of TPX2 with the acetylated α-tubulin. |
|
体内研究 (In Vivo) | LLP-3 (intraperitoneal injection, 25 mg/kg, for 10 days) prolongs survival of GBM sphere-derived tumor mice[1].
Animal Model: | GBM sphere-derived tumor models (GBM83 and 1600)[1] | Dosage: | 25 mg/kg | Administration: | Intraperitoneal injection, for 10 days (days 10–14 and days 17–21) | Result: | Prolonged the survival of tumor-burden mice without exhibiting any lethality of mice until day 35. |
|
分子量 | |
Formula | |
CAS 号 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |